Skip to main content

COVID-19 Archives

One Hundred Oaks COVID-19 vaccination site to close April 7

Mar. 30, 2023—The COVID-19 vaccination site at Vanderbilt Health One Hundred Oaks will close on April 7.

Read more


COVID-19 vaccination site at One Hundred Oaks to close April 7

Mar. 23, 2023—The COVID-19 vaccination site at Vanderbilt Health One Hundred Oaks will close on April 7. Since the COVID-19 vaccine became available in late 2020, VUMC has administered 257,000 doses of the vaccine. “We are grateful to all our staff who have made this program a success,” said Patty Wright, MD, professor of Medicine and Chief...

Read more


Crowe’s research honored

Mar. 23, 2023—Vanderbilt's James Crowe Jr., MD, was among those to receive 2023 Advocacy Awards from Research!America at the biomedical research advocacy organization’s annual awards program in Washington, D.C.

Read more


Study finds RSV may evade vaccines via rapid mutation

Mar. 9, 2023—A Vanderbilt study concluded that RSV’s ability to mutate rapidly to escape detection by the body’s immune system makes it more challenging to design and develop vaccines that can stop it from spreading.

Read more


COVID-19 battle begins in the nose

Feb. 2, 2023—A high upper airway concentration of the virus that causes COVID-19 was associated with changes in gene expression that could impact disease progression, Vanderbilt researchers discovered.

Read more


Study to explore COVID’s impact on essential workers

Jan. 26, 2023—Vanderbilt researchers are inviting non-health care essential workers to participate in a study to better understand how they continue to be impacted by COVID-19.

Read more


Emerging Infections Program lands national award for COVID response

Jan. 19, 2023—Vanderbilt's Emerging Infections Program (EIP) recently received the Toby Merlin Award for Excellence in Emergency Response, presented by the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry.

Read more


VUMC-led COVID-19 clinical trial platform goes international

Jan. 5, 2023—The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.

Read more


VUMC strongly recommends COVID-19 bivalent booster vaccination as new COVID-19 variants appear in our region

Jan. 4, 2023—With the development of new variants of the COVID-19 virus across the U.S. and the world, Vanderbilt University Medical Center recommends getting the bivalent booster vaccination.

Read more


Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults

Dec. 16, 2022—The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.

Read more


Surgical risk persists for patients who’ve had COVID

Dec. 14, 2022—Vanderbilt researchers report that the trend of decreasing postoperative risk for people who have had COVID persists longer than previously known, for as long as 13 months after COVID.

Read more


AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

Nov. 10, 2022—On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more